Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae

被引：20
作者：
Chau, Andrew S. [1 ]
Chen, Guodong [1 ]
McNicholas, Paul M. [1 ]
Mann, Paul A. [1 ]
机构：
[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 11期
关键词：
D O I：
10.1128/AAC.00747-06
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Posaconazole and itraconazole were more potent inhibitors of ergosterol synthesis, in both intact cells and cell extracts from Absidia corymbifera and Rhizopus oryzae, than voriconazole and fluconazole. Similarly, expression of CYP51 from R. oryzae in Saccharomyces cerevisiae significantly increased resistance to fluconazole and voriconazole but not to posaconazole and itraconazole.
引用
收藏
页码：3917 / 3919
页数：3
相关论文
共 16 条
  • [1] BALLARD SA, 1990, J MED VET MYCOL, V28, P327
  • [2] A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole
    Calabrese, D
    Bille, J
    Sanglard, D
    [J]. MICROBIOLOGY-UK, 2000, 146 : 2743 - 2754
  • [3] Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to Azoles
    Chau, AS
    Mendrick, CA
    Sabatelli, FJ
    Loebenberg, D
    McNicholas, PM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2124 - 2131
  • [4] *CLIN LAB STAND I, 2002, M38A NAT COMM LAB ST
  • [5] Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil
    Goldman, GH
    Ferreira, MED
    Marques, ED
    Savoldi, M
    Perlin, D
    Park, S
    Martinez, PCG
    Goldman, MHS
    Colombo, AL
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 50 (01) : 25 - 32
  • [6] Posaconazole as salvage therapy for zygomycosis
    Greenberg, RN
    Mullane, K
    van Burik, JAH
    Raad, I
    Abzug, MJ
    Anstead, G
    Herbrecht, R
    Langston, A
    Marr, KA
    Schiller, G
    Schuster, M
    Wingard, JR
    Gonzalez, CE
    Revankar, SG
    Corcoran, G
    Kryscio, RJ
    Hare, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) : 126 - 133
  • [7] Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections
    Herbrecht, R
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (06) : 612 - 624
  • [8] Y132H substitution in Candida albicans sterol 14α-demethylase confers fluconazole resistance by preventing binding to haem
    Kelly, SL
    Lamb, DC
    Kelly, DE
    [J]. FEMS MICROBIOLOGY LETTERS, 1999, 180 (02) : 171 - 175
  • [9] Zygomycosis in a Tertiary-Care Cancer Center in the era of Aspergillus-active antifungal therapy:: A case-control observational study of 27 recent cases
    Kontoyiannis, DP
    Lionakis, MS
    Lewis, RE
    Chamilos, G
    Healy, M
    Perego, C
    Safdar, A
    Kantarjian, H
    Champlin, R
    Walsh, TJ
    Raad, II
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (08) : 1350 - 1360
  • [10] Effects of Y132H and F145L substitutions on the activity, azole resistance and spectral properties of Candida albicans sterol 14-demethylase P450 (CYP51):: A live example showing the selection of altered P450 through interaction with environmental compounds
    Kudo, M
    Ohi, A
    Aoyama, Y
    Nitahara, Y
    Chung, SK
    Yoshida, Y
    [J]. JOURNAL OF BIOCHEMISTRY, 2005, 137 (05) : 625 - 632
12